Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Brain tissue and pathology

Topic: Brain proteins, microglia and lab models

Neurodegeneration in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) results from both gain of toxicity and loss of normal function of the RNA-binding protein TDP-43, but their mechanistic connection remains unclear. Increasing evidence suggests that TDP-43 aggregates act as self-templating seeds, propagating pathology through the central nervous system via a prion-like cascade. We developed a robust TDP-43-seeding platform for quantitative assessment of TDP-43 aggregate uptake, cell-to-cell spreading, and loss of function within living cells, while they progress toward pathology. We show that both patient-derived and recombinant TDP-43 pathological aggregates were abundantly internalized by human neuron-like cells, efficiently recruited endogenous TDP-43, and formed cytoplasmic inclusions reminiscent of ALS/FTD pathology. Combining a fluorescent reporter of TDP-43 function with RNA sequencing and proteomics, we demonstrated aberrant cryptic splicing and a loss-of-function profile resulting from TDP-43-templated aggregation. Our data highlight known and novel pathological signatures in the context of seed-induced TDP-43 loss of function.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Scialò, C., Zhong, W., Jagannath, S., Wilkins, O. G., Caredio, D., Hruška-Plocháň, M., et al. (2025). Seeded aggregation of TDP-43 induces its loss of function and reveals early pathological signatures. Neuron. https://doi.org/10.1016/j.neuron.2025.03.008

Vancouver

Scialò C, Zhong W, Jagannath S, Wilkins OG, Caredio D, Hruška-Plocháň M, et al. Seeded aggregation of TDP-43 induces its loss of function and reveals early pathological signatures. Neuron. 2025. doi:10.1016/j.neuron.2025.03.008. PMID: 40157355.

BibTeX

@article{scialo2025-40157355,
  author  = {Scialò, Carlo and Zhong, Weijia and Jagannath, Somanath and Wilkins, Oscar G. and Caredio, Davide and Hruška-Plocháň, Marián and Lurati, Flavio and Peter, Martina and others},
  title   = {{Seeded aggregation of TDP-43 induces its loss of function and reveals early pathological signatures}},
  journal = {Neuron},
  year    = {2025},
  doi     = {10.1016/j.neuron.2025.03.008},
  pmid    = {40157355},
  url     = {https://doi.org/10.1016/j.neuron.2025.03.008}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

Using a cell-based seeding platform, this study showed that TDP-43 aggregates can be taken up by human neuron-like cells, recruit normal TDP-43 and cause loss of function. These are laboratory findings about how pathology may spread, not a treatment or prevention for patients.

Study details

How this study scored 35/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record left out, no data; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 1 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 2 of 4; Institution's track record left out, no data; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. 33 of the 93 points it could be judged on, which is 35 of 100. Total 35 of 100.33 of the 93 points we could judge = 35 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record and institution's track record, so those were left out: it earned 33 of the 93 points we could judge it on, which is 35 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Neuron)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 4 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.3 citations a year over 3 year(s) since 2025
Impact for its field and year 2 / 6 Cited 2.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Magdalini Polymenidou: h-index 42 (OpenAlex, whole career)
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration 0 / 3 OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40157355)
Free to read 2 / 2 Free to read
Points 33 / 93 Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 33 of the 93 points we could judge it on is 35 out of 100.
Total 35 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Brain tissue and pathology

Also tagged “tdp-43”

1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Brain tissue and pathology

See all studies in Brain tissue and pathology →